Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus DYNACIRC CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus DYNACIRC CR.
DILACOR XR vs DYNACIRC CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
Isradipine extended-release (DynaCirc CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker